Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.92
HZNP's Cash to Debt is ranked lower than
63% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. HZNP: 0.92 )
Ranked among companies with meaningful Cash to Debt only.
HZNP' s 10-Year Cash to Debt Range
Min: 0.07  Med: 1.18 Max: N/A
Current: 0.92
Equity to Asset 0.45
HZNP's Equity to Asset is ranked lower than
76% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. HZNP: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
HZNP' s 10-Year Equity to Asset Range
Min: -0.77  Med: 0.48 Max: 0.7
Current: 0.45
-0.77
0.7
F-Score: 4
Z-Score: 3.92
M-Score: -0.33
WACC vs ROIC
11.71%
8.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1.48
HZNP's Operating margin (%) is ranked lower than
75% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. HZNP: -1.48 )
Ranked among companies with meaningful Operating margin (%) only.
HZNP' s 10-Year Operating margin (%) Range
Min: -1841.5  Med: -418.56 Max: -2.86
Current: -1.48
-1841.5
-2.86
Net-margin (%) -21.47
HZNP's Net-margin (%) is ranked lower than
84% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. HZNP: -21.47 )
Ranked among companies with meaningful Net-margin (%) only.
HZNP' s 10-Year Net-margin (%) Range
Min: -1635.12  Med: -465.90 Max: -88.77
Current: -21.47
-1635.12
-88.77
ROE (%) -24.57
HZNP's ROE (%) is ranked lower than
82% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. HZNP: -24.57 )
Ranked among companies with meaningful ROE (%) only.
HZNP' s 10-Year ROE (%) Range
Min: -523.78  Med: -115.60 Max: -57.66
Current: -24.57
-523.78
-57.66
ROA (%) -8.71
HZNP's ROA (%) is ranked lower than
78% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. HZNP: -8.71 )
Ranked among companies with meaningful ROA (%) only.
HZNP' s 10-Year ROA (%) Range
Min: -176.97  Med: -63.12 Max: -31.86
Current: -8.71
-176.97
-31.86
ROC (Joel Greenblatt) (%) -56.66
HZNP's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. HZNP: -56.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HZNP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4895.85  Med: -2664.68 Max: -154.09
Current: -56.66
-4895.85
-154.09
Revenue Growth (3Y)(%) 66.40
HZNP's Revenue Growth (3Y)(%) is ranked higher than
97% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. HZNP: 66.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HZNP' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -7.30 Max: 66.4
Current: 66.4
0
66.4
EPS Growth (3Y)(%) -36.90
HZNP's EPS Growth (3Y)(%) is ranked lower than
88% of the 451 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. HZNP: -36.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HZNP' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -26.00 Max: -36.9
Current: -36.9
» HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

HZNP Guru Trades in Q3 2014

Paul Tudor Jones 294,814 sh (New)
Steven Cohen 934,396 sh (New)
Joel Greenblatt 80,834 sh (+39.93%)
» More
Q4 2014

HZNP Guru Trades in Q4 2014

Steven Cohen 2,614,700 sh (+179.83%)
Joel Greenblatt 107,898 sh (+33.48%)
Paul Tudor Jones 274,577 sh (-6.86%)
» More
Q1 2015

HZNP Guru Trades in Q1 2015

Jim Simons 359,430 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones 45,508 sh (-83.43%)
Steven Cohen 233,900 sh (-91.05%)
» More
2015

HZNP Guru Trades in 2015

Steve Mandel 8,353,668 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Horizon Pharma PLC

Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma
Steven Mandel’s hedge fund, Lone Pine Capital, on July 27 initiated a position in Horizon Pharma Plc (NASDAQ:HZNP), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
Forward P/E 13.97
HZNP's Forward P/E is ranked higher than
84% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. HZNP: 13.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 6.92
HZNP's P/B is ranked lower than
76% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. HZNP: 6.92 )
Ranked among companies with meaningful P/B only.
HZNP' s 10-Year P/B Range
Min: 0.8  Med: 2.30 Max: 14.89
Current: 6.92
0.8
14.89
P/S 10.22
HZNP's P/S is ranked lower than
81% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. HZNP: 10.22 )
Ranked among companies with meaningful P/S only.
HZNP' s 10-Year P/S Range
Min: 1.47  Med: 4.69 Max: 19.46
Current: 10.22
1.47
19.46
Current Ratio 3.75
HZNP's Current Ratio is ranked higher than
68% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. HZNP: 3.75 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s 10-Year Current Ratio Range
Min: 0.16  Med: 1.69 Max: 4.39
Current: 3.75
0.16
4.39
Quick Ratio 3.68
HZNP's Quick Ratio is ranked higher than
73% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. HZNP: 3.68 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s 10-Year Quick Ratio Range
Min: 0.16  Med: 1.58 Max: 4.27
Current: 3.68
0.16
4.27
Days Inventory 53.25
HZNP's Days Inventory is ranked higher than
82% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. HZNP: 53.25 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s 10-Year Days Inventory Range
Min: 13.1  Med: 59.25 Max: 184.95
Current: 53.25
13.1
184.95
Days Sales Outstanding 129.69
HZNP's Days Sales Outstanding is ranked lower than
81% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. HZNP: 129.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s 10-Year Days Sales Outstanding Range
Min: 67.08  Med: 88.33 Max: 124.99
Current: 129.69
67.08
124.99

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 42.27
HZNP's Price/Projected FCF is ranked lower than
97% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. HZNP: 42.27 )
Ranked among companies with meaningful Price/Projected FCF only.
HZNP' s 10-Year Price/Projected FCF Range
Min: 14.99  Med: 29.51 Max: 409.33
Current: 42.27
14.99
409.33
Price/Median PS Value 2.22
HZNP's Price/Median PS Value is ranked lower than
77% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. HZNP: 2.22 )
Ranked among companies with meaningful Price/Median PS Value only.
HZNP' s 10-Year Price/Median PS Value Range
Min: 0.37  Med: 1.02 Max: 3.71
Current: 2.22
0.37
3.71
Earnings Yield (Greenblatt) (%) -0.10
HZNP's Earnings Yield (Greenblatt) (%) is ranked lower than
71% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. HZNP: -0.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HZNP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1.1  Med: 0.00 Max: 0
Current: -0.1
-1.1
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
Horizon Pharma plc Announces Collaboration With Fox Chase Cancer Center to Study ACTIMMUNE(R) (inter Jul 27 2015 
Horizon Pharma plc Increases Offer for Depomed, Inc. to $33.00 per Share Jul 21 2015 
Horizon Pharma plc Expects Record Net Sales Results for Second Quarter 2015 and Raises Full-Year 201 Jul 20 2015 
Horizon Pharma plc Responds to Depomed's Adoption of a Poison Pill Jul 13 2015 
Horizon Pharma plc Files Patent Infringement Lawsuits Against Five Companies for Filing Abbreviated Jul 06 2015 
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice o Jul 02 2015 
hznp May 24 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 

More From Other Websites
Ahead of the Bell: Depomed rejects Horizon offer Jul 30 2015
Ahead of the Bell: Depomed rejects Horizon offer Jul 30 2015
DepoMed Raises Guidance Jul 29 2015
Depomed rejects Horizon Pharma's latest bid Jul 29 2015
Depomed Rejects Horizon Pharma’s Takeover Proposal as Inadequate Jul 29 2015
Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited... Jul 29 2015
Stephen Mandel Initiates New Position in Horizon Pharma PLC (HZNP), Up 200% This Year Jul 29 2015
Mandel's Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015
HORIZON PHARMA PLC Files SEC form 8-K/A, Other Events, Financial Statements and Exhibits Jul 27 2015
Horizon Pharma plc Announces Collaboration With Fox Chase Cancer Center to Study ACTIMMUNE(R)... Jul 27 2015
Horizon Pharma plc Announces Collaboration With Fox Chase Cancer Center to Study ACTIMMUNE(R)... Jul 27 2015
Dealpolitik: Depomed Makes the Best of Weak Takeover Defenses Jul 24 2015
Top Plays Carry Mark Kingdon’s Picks To Strong Q2 Jul 23 2015
Horizon Pharma Up on Expected Q2 Sales, 2015 Outlook - Analyst Blog Jul 21 2015
Horizon Raises Bid for Specialty Pharma Company Depomed Jul 21 2015
HORIZON PHARMA PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 21 2015
Horizon raises offer for rival drugmaker Depomed Jul 21 2015
Horizon Pharma raises bid for Depomed to $33 per share Jul 21 2015
Horizon Pharma raises bid for Depomed to $33 per share Jul 21 2015
Horizon Pharma raises offer again to buy reluctant Depomed Jul 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK